Results 61 to 70 of about 5,464,915 (400)
An integrated molecular and conventional breeding scheme for enhancing genetic gain in maize in Africa [PDF]
, 2020 Open Access Journal; Published online: 06 Nov 2019Maize production in West and Central Africa (WCA) is constrained by a wide range of interacting stresses that keep productivity below potential yields.
Gedil, M., Menkir, A.
core +1 more source
Infection Models for Pine Wilt Disease on the Basis of Vector Behaviors
Population Ecology, EarlyView.Infection models for pine wilt disease without vector density were built to estimate the transmission coefficient of the pathogenic nematode. The models successfully simulated the annual change in the density of infected trees for four pine stands. ABSTRACT Pine wilt disease is caused by the pinewood nematode (Bursaphelenchus xylophilus Steiner et ...
Katsumi Togashi
wiley +1 more source
Genetic markers on chromosome 7. [PDF]
Journal of Medical Genetics, 1988 Chromosome 7 is frequently associated with chromosome aberrations, rearrangements, and deletions. It also contains many important genes, gene families, and disease loci. This brief review attempts to summarise these and other interesting aspects of chromosome 7.
openaire +5 more sources
Are current ecological restoration practices capturing natural levels of genetic diversity? A New Zealand case study using AFLP and ISSR data from mahoe (Melicytus ramiflorus) [PDF]
, 2015 Sourcing plant species of local provenance (eco-sourcing) has become standard practice in plant community restoration projects. Along with established ecological restoration practices, knowledge of genetic variation in existing and restored forest ...
Clarke, Andrew C. +4 more
core +2 more sources
Population Ecology, EarlyView.Population size and dynamics fundamentally shape speciation by influencing genetic drift, founder events, and adaptive potential. Small populations may speciate rapidly due to stronger drift, whereas large populations harbor more genetic diversity, which can alter divergence trajectories. We highlight theoretical models that incorporate population size
Ryo Yamaguchi +3 more
wiley +1 more source
FoxO1 signaling in B cell malignancies and its therapeutic targeting
FEBS Letters, EarlyView.FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac +3 more
wiley +1 more source
Leishmania Resistance to Miltefosine Associated with Genetic Marker
Emerging Infectious Diseases, 2012 To the Editor: During 2000–2010, serial Leishmania isolates obtained from an HIV-infected patient who was not responding to treatment showed a gradual decrease in in vitro miltefosine susceptibility. We performed L. donovani miltefosine transporter (Ldmt)
S. Cojean +11 more
semanticscholar +1 more source
Genetic Dissection of Disease Resistance to the Blue Mold Pathogen, Peronospora tabacina, in Tobacco
Agronomy, 2015 Tobacco blue mold, caused by the obligately biotrophic oomycete pathogen Peronospora tabacina D.B. Adam, is a major foliar disease that results in significant losses in tobacco-growing areas. Natural resistance to P.
Xia Wu +5 more
doaj +1 more source
Differentiation of Aspergillus flavus from Aspergillus oryzae Targeting the cyp51A Gene
Pathogens, 2021 Aspergillus flavus is one of the most important agents of invasive and non-invasive aspergillosis, especially in tropical and subtropical regions of the world, including Iran. Aspergillus oryzae is closely related to A.
Sanaz Nargesi +6 more
doaj +1 more source
Insights into PI3K/AKT signaling in B cell development and chronic lymphocytic leukemia
FEBS Letters, EarlyView.This Review explores how the phosphoinositide 3‐kinase and protein kinase B pathway shapes B cell development and drives chronic lymphocytic leukemia, a common blood cancer. It examines how signaling levels affect disease progression, addresses treatment challenges, and introduces novel experimental strategies to improve therapies and patient outcomes.
Maike Buchner
wiley +1 more source